FOCR offers path for validating ctDNA as an early endpoint for drug approval

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsDiagnostics/IVDsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy